Gazdar Adi, Robinson Linda, Oliver Dwight, Xing Chao, Travis William D, Soh Junichi, Toyooka Shinichi, Watumull Lori, Xie Yang, Kernstine Kemp, Schiller Joan H
*Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX; †Department of Pathology, UT Southwestern Medical Center, Dallas, TX; ‡Cancer Genetics, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX; §Department of Clinical Science and McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, TX; ‖Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; ¶Department of Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan; #Department of Radiology, UT Southwestern Medical Center, Dallas, TX; **Department of Clinical Science and Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX; ††Department of Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX; and ‡‡Department of Medicine and Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX.
J Thorac Oncol. 2014 Apr;9(4):456-63. doi: 10.1097/JTO.0000000000000130.
Hereditary lung cancer syndromes are rare, and T790M germline mutations of the epidermal growth factor receptor (EGFR) gene predispose to the development of lung cancer. The goal of this study was to determine the clinical features and smoking status of lung cancer cases and unaffected family members with this germline mutation and to estimate its incidence and penetrance.
We studied a family with germline T790M mutations over five generations (14 individuals) and combined our observations with data obtained from a literature search (15 individuals).
T790M germline mutations occurred in approximately 1% of non-small-cell lung cancer cases and in less than one in 7500 subjects without lung cancer. Both sporadic and germline T790M mutations were predominantly adenocarcinomas, favored female gender, and were occasionally multifocal. Of lung cancer tumors arising in T790M germline mutation carriers, 73% contained a second activating EGFR gene mutation. Inheritance was dominant. The odds ratio that T790M germline carriers who are smokers will develop lung cancer compared with never smoker carriers was 0.31 (p = 6.0E-05). There was an overrepresentation of never smokers with lung cancer with this mutation compared with the general lung cancer population (p = 7.4E-06).
Germline T790M mutations result in a unique hereditary lung cancer syndrome that targets never smokers, with a preliminary estimate of 31% risk for lung cancer in never smoker carriers, and this risk may be lower for heavy smokers. The resultant cancers share several features and differences with lung cancers containing sporadic EGFR mutations.
遗传性肺癌综合征较为罕见,表皮生长因子受体(EGFR)基因的T790M种系突变易引发肺癌。本研究的目的是确定携带这种种系突变的肺癌病例及未受影响家庭成员的临床特征和吸烟状况,并估计其发病率和外显率。
我们研究了一个有五代人(14名个体)携带种系T790M突变的家族,并将我们的观察结果与从文献检索中获得的数据(15名个体)相结合。
T790M种系突变约发生在1%的非小细胞肺癌病例中,在7500名无肺癌的受试者中发生率不到1/7500。散发性和种系T790M突变主要为腺癌,以女性居多,偶尔为多灶性。在T790M种系突变携带者中发生的肺癌肿瘤,73%含有第二个激活的EGFR基因突变。遗传方式为显性。与从不吸烟的携带者相比,吸烟的T790M种系携带者患肺癌的优势比为0.31(p = 6.0E - 05)。与一般肺癌人群相比,携带这种突变的肺癌患者中从不吸烟者的比例过高(p = 7.4E - 06)。
种系T790M突变导致一种独特的遗传性肺癌综合征,其靶向从不吸烟者,初步估计从不吸烟的携带者患肺癌的风险为31%,而重度吸烟者的风险可能较低。由此产生的癌症与含有散发性EGFR突变的肺癌有一些共同特征和差异。